Advertisement

Captopril and Hypertension

  • David B. Case
  • Edmund H. Sonnenblick
  • John H. Laragh

Part of the Topics in Cardiovascular Disease book series (TCAD)

Table of contents

  1. Front Matter
    Pages i-xi
  2. Humoral and Physiological Mechanisms in Hypertension

    1. Front Matter
      Pages 1-1
    2. Robert A. Vukovich, James R. Knill
      Pages 3-13
    3. Emmanuel L. Bravo, Harriet P. Dustan, Robert C. Tarazi
      Pages 15-23
    4. Jay N. Cohn
      Pages 77-86
  3. Angiotensin-Converting Enzyme

    1. Front Matter
      Pages 87-87
    2. Richard L. Soffer, Edmund H. Sonnenblick
      Pages 89-102
    3. David W. Cushman, Hong Son Cheung, Emily F. Sabo, Miguel A. Ondetti
      Pages 103-113
    4. Bernard Rubin, Michael J. Antonaccio, Zola P. Horovitz
      Pages 115-135
    5. Hans R. Brunner, Haralambos Gavras, B. Waeber, G. A. Turini, J. P. Wauters
      Pages 149-170
  4. Clinical Use of Converting Enzyme Inhibitors

    1. Front Matter
      Pages 171-171
    2. Haralambos Gavras, Irene Gavras, Stephen Textor, Charles P. Tifft, Glenn R. Kershaw, Hans R. Brunner
      Pages 201-210
    3. David B. Case, Steven A. Atlas, John H. Laragh, Jean E. Sealey, Patricia A. Sullivan, Doris N. McKinstry
      Pages 211-230
  5. Back Matter
    Pages 231-236

About this book

Introduction

This monograph was developed from a collection of papers that were origi­ nally presented at a symposium entitled "Pathogenesis of Hypertension" held at the Henry Chauncy Conference Center, Princeton. New Jersey. These manuscripts were subsequently revised, updated, and reorganized in a manner suitable for this publication. The symposium was planned to stimu­ late interest among investigators and clinicians alike in the potential for a new class of drugs called converting enzyme inhibitors in clinical medicine. The meeting was sponsored by the Squibb Institute for Medical Research, whose pioneering biochemical and pharmaceutical research had led to the development of the first orally active converting enzyme inhibitor. It is hoped that this monograph will cohesively pull together the thesis that the identification, quantification, and containment of the renin factor in hypertension can be a powerful diagnostic and therapeutic strategy in clinical medicine. In addition, the sequence of studies presented in this manuscript will serve to demonstrate how basic biochemical and physio­ logical research produces fundamental and critical information on which subsequent major advances in clinical pharmacology and medicine can be based.

Keywords

blood pressure development drugs hypertension medicine pathogenesis pharmacology research

Editors and affiliations

  • David B. Case
    • 1
  • Edmund H. Sonnenblick
    • 2
  • John H. Laragh
    • 1
  1. 1.New York Hospital/Cornell Medical CenterNew YorkUSA
  2. 2.Albert Einstein College of MedicineThe BronxUSA

Bibliographic information